cox-2 inhibitor

(redirected from Cyclooxygenase-2 inhibitor)
Also found in: Dictionary, Thesaurus, Medical.

cox-2 inhibitor:

see nonsteroidal anti-inflammatory drugnonsteroidal anti-inflammatory drug,
a drug that suppresses inflammation in a manner similar to steroids, but without the side effects of steroids; commonly referred to by the acronym NSAID .
..... Click the link for more information.
.
References in periodicals archive ?
Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 Inhibitors.
Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt induced hypertension.
NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.
For patients who are at GI risk, a selective cyclooxygenase-2 inhibitor is recommended, he said.
For instance, 17% were taking an NSAID or a cyclooxygenase-2 inhibitor, 41% were taking aspirin or clopidogrel, and 24% were on Coumadin or enoxaparin.
85 billion into a fund to settle claims that its cyclooxygenase-2 inhibitor rofecoxib (Vioxx) was responsible for causing myocardial infarction and stroke in patients who took the drug for pain.
Investigators in an ongoing primary prevention trial of rofecoxib, a cyclooxygenase-2 inhibitor, and naproxen, a nonselective NSAID, propose to enroll 2,700 study participants and follow them for 5 years.
The Food and Drug Administration has issued a "not approvable" letter on the cyclooxygenase-2 inhibitor lumiracoxib for osteoarthritic pain.
Now that the future availability of at least one selective cyclooxygenase-2 inhibitor appears certain, physicians will need better guidance on how to weigh risks and benefits--and avoid liability--when treating individual patients.
HONOLULU -- Rofecoxib, a selective cyclooxygenase-2 inhibitor, significantly reduced the frequency of perimenstrual migraine headaches in a small, open-label trial.
Giesler gave 50 mg of the cyclooxygenase-2 inhibitor rofecoxib (Vioxx) on the morning of surgery to 13 patients.
At that meeting, the panelists also voted 16-9 that there were not enough data to suggest that naproxen presented a substantially lower risk of CV events than did either ibuprofen or selective NSAIDs, such as cyclooxygenase-2 inhibitors.

Full browser ?